By: Dr. Mercola
01 November 2010
It’s been four years since Gardasil debuted as a blockbuster vaccine with sales that rocketed to over $1.1 billion in its first nine months.
Touted as a wonder vaccine that would end cervical cancer, it was supposed to be the savior of both mankind and Merck’s Vioxx-damaged bottom line. But now, according to CNN Money, it’s a dud.
It just posted $219 million in sales. But in the pharma world, that’s a paltry pittance, nothing short of an in-flight explosion that’s caused Merck stock to drop 3 percent, with analysts and investors scrambling to figure out what went wrong.
So what happened?
How did a vaccine that was supposed to be Merck’s beacon for higher profits in the 21st Century go from flagship to flop?
Read the entire article here.